Ocular pharmacology

Ophthalmic diseases include both those analogous to systemic diseases (eg, inflammation, infection, neuronal degeneration) and not analogous (eg, cataract, myopia). Many anterior segment diseases are treated pharmacologically through eye drops, which have an implied therapeutic index of local therapy. Unlike oral dosage forms administered for systemic diseases, eyedrops require patients not only to adhere to treatment, but to be able to accurately perform—ie, instill drops correctly.Anatomical and physiological barriers make topical delivery to the anterior chamber challenging—in some cases more challenging than absorption through the skin, nasal passages, or gut. Treatment of the posterior segment (eg, vitreous, retina, choroid, and optic nerve) is more challenging due to additional barriers. Recently, intravitreal injections have become a standard of care with biologics for the treatment of macular degeneration and other diseases. Although the eye has esterases, hydroxylases, and transporters, it has relatively little CYP450 enzymes. Because it is challenging to obtain drug concentrations at the target site, ocular clinical pharmacokinetics, and thus pharmacokinetic‐pharmacodynamic interactions, are rarely available. Ophthalmic pharmaceuticals require consideration of solubility, physiological pH, and osmolarity, as well as sterility and stability, which in turn requires optimal pharmaceutics. Although applied locally, ocular medications may be absorbed systemically, which results in morbidity and mortality (eg, systemic hypotension, bronchospasm, and bradycardia).Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136697/1/jcph634_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/136697/2/jcph634.pd

Report of the Inaugural Meeting of the TFOS i2 = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment

In March 2015, a meeting was held in London, United Kingdom, to address the progress in targeting the unmet need for dry eye disease (DED) treatment. The meeting, which launched the i2 = initiating innovation series, was sponsored by the Tear Film & Ocular Surface Society (TFOS; www.TearFilm.org) and supported by Dompé. The TFOS i2 meeting was designed to review advances in the understanding of DED since publication of the 2007 TFOS International Dry Eye WorkShop (DEWS) report, and to help launch the highly anticipated sequel, DEWS II. The meeting was structured to discuss the scope of the DED problem, to review the clinical challenges of DED, and to consider the treatment challenges of DED. This article provides a synopsis of the presentations of this TFOS i2 meeting

TFOS DEWS II Report Executive Summary

This article presents an Executive Summary of the conclusions and recommendations of the 10-chapter TFOS DEWS II report. The entire TFOS DEWS II report was published in the July 2017 issue of The Ocular Surface. A downloadable version of the document and additional material, including videos of diagnostic and management techniques, are available on the TFOS website: www.TearFilm.org

Venus Observations at 40 and 90 GHz with CLASS

Using the Cosmology Large Angular Scale Surveyor, we measure the disk-averaged absolute Venus brightness temperature to be 432.3 $\pm$ 2.8 K and 355.6 $\pm$ 1.3 K in the Q and W frequency bands centered at 38.8 and 93.7 GHz, respectively. At both frequency bands, these are the most precise measurements to date. Furthermore, we observe no phase dependence of the measured temperature in either band. Our measurements are consistent with a CO$_2$-dominant atmospheric model that includes trace amounts of additional absorbers like SO$_2$ and H$_2$SO$_4$.Comment: 7 pages, 3 figures, published in PS